Income and location divide in myeloma outcomes: A call for equitable care.

e19544 Background: Myeloma, a hematologic malignancy with rising incidence, has seen significant advancements in treatment over the past two decades. However, the benefits of novel therapies may not be equitably distributed across populations. This study analyzes incidence-based mortality (IBM) trends for myeloma between 2000-2021, focusing on disparities by household income and geographic location. By identifying these inequities, the study aims to inform strategies for improving healthcare access and outcomes. Methods: Data were obtained from the SEER database (17 registries, Nov 2023 submission). IBM rates were stratified by household income levels (<$40k, $60k+, $100k+, $120k+) and residence in metropolitan versus non-metropolitan counties. Trends were analyzed using Joinpoint regression software to quantify changes over time. Results: IBM rates were inversely correlated with household income, ranging from 7.3 per 100,000 for incomes <$40k to 5.31 per 100,000 for incomes $120k+. Residents of non-metropolitan counties exhibited slightly higher IBM rates (6.14 per 100,000) compared to metropolitan counties (5.94 per 100,000). While all groups experienced a gradual decline in IBM rates over time, disparities persisted, with lower-income and non-metropolitan populations exhibiting consistently higher mortality. Conclusions: The study highlights significant inequities in myeloma outcomes based on income and residence, likely driven by differences in access to novel therapies, healthcare resources, and insurance coverage. These findings call for targeted interventions to reduce these disparities and further research to address the underlying causes, ensuring equitable access to advancements in myeloma care.